SCHEMBL21796368

SCHEMBL21796368

COc1cc(Cl)ccc1CNc1cc(Cl)c2ccccc2n1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRK6 P43250 3/20 0.56
NPSR1 Q6W5P4 2/20 0.47
MAPT P10636 2/20 0.47
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
KDM4E B2RXH2 2/20 0.47
RXFP1 Q9HBX9 1/20 0.47
SLC2A1 P11166 2/20 0.47
CYP1A2 P05177 6/20 0.47
CYP3A4 P08684 6/20 0.47
CYP2D6 P10635 6/20 0.47
CYP2C19 P33261 6/20 0.47
TSHR P16473 5/20 0.47
LMNA P02545 4/20 0.47
HSD17B10 Q99714 2/20 0.47
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
USP2 O75604 3/20 0.46
ALOX15 P16050 3/20 0.46
CLK4 Q9HAZ1 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21796382 0.80 APP (0.52) ALDH1A1SMN1; SMN2KDM4ESLC2A1CYP1A2
SCHEMBL3268661 0.77 NPSR1 (0.54) NPSR1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL17713558 0.77 KDM4E (0.58) MAPTALDH1A1SMN1; SMN2KDM4ELMNA
SCHEMBL21796420 0.77 NCF1 (0.59) MAPTALDH1A1SMN1; SMN2KDM4ESLC2A1
SCHEMBL21796392 0.76 GRK6 (0.44) GRK6NPSR1MAPTALDH1A1SMN1; SMN2
SCHEMBL3267078 0.76 ALDH1A1 (0.53) NPSR1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL21796417 0.75 KDM4E (0.68) NPSR1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL3268434 0.74 NTRK1 (0.43) GRK6NPSR1MAPTALDH1A1SMN1; SMN2
SCHEMBL28890431 0.73 MEN1 (0.59) NPSR1MAPTALDH1A1SMN1; SMN2KDM4E
SCHEMBL3267862 0.72 NPSR1 (0.48) GRK6NPSR1MAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11261189-B2 Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases GENOSCIENCE PHARMA (FR) 2022-03-01 US disclosed
EP-3846814-A1 SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES Genoscience Pharma (FR) 2021-07-14 EP disclosed
CN-112912081-A Substituted 2, 4-diamino-quinolines as novel agents for fibrosis, autophagy and cathepsin B (CTSB), L (CTSL) and D (CTSD) related diseases 基因科学医药公司 2021-06-04 CN disclosed
US-20200079781-A1 Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases GENOSCIENCE PHARMA (FR) 2020-03-12 US disclosed
EP-3620164-A1 SUBSTITUTED 2,4 DIAMINO-QUINOLINE AS NEW MEDICAMENT FOR FIBROSIS, AUTOPHAGY AND CATHEPSINS B (CTSB), L (CTSL) AND D (CTSD) RELATED DISEASES Genoscience Pharma SAS (FR) 2020-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200079781-A1 Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases CTSB, CTSD, CTSA GRK6 4278/4885NPSR1 2088/4885MAPT 1642/4885
US-11261189-B2 Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseases CTSB, CTSD, CTSA GRK6 4278/4885NPSR1 2088/4885MAPT 1642/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.